Robert A Phillips
Affiliation: University of Massachusetts Medical School
- Another boost for cardiac rehabilitationRobert A Phillips
Heart and Vascular Center of Excellence, University of Massachusetts Memorial Medical Center, 55 Lake St N, S3 434, Worcester, MA 01655, USA
Arch Intern Med 168:1029. 2008
- A review of therapeutic strategies for risk reduction of recurrent strokeRobert A Phillips
University of Massachusetts Medical School, University of Massachusetts Memorial Medical Center, Worcester, MA 01655, USA
Prog Cardiovasc Dis 50:264-73. 2008..The ongoing, large-scale, comparative Prevention Regimen for Effectively Avoiding Second Strokes (PR. FESS) trial should provide cardiologists with more definitive recommendations...
- Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (Robert A Phillips
University of Massachusetts Medical School, Worcester, MA, USA
J Cardiometab Syndr 3:211-7. 2008..Carvedilol effects were favorable to adjustment of age as a covariate. In hypertensive patients with diabetes, carvedilol may be a more appropriate choice when beta-blockade is indicated...
- When things go wrong: the impact of being a statistical outlier in publicly reported coronary artery bypass graft surgery mortality dataWalter H Ettinger
UMass Memorial Medical Center, Worcester, Massachusetts 01655, USA
Am J Med Qual 23:90-5. 2008..Several lessons were learned that may be of value to other health care organizations that experience a public crisis in clinical quality...
- Controversies in blood pressure goal guidelines and masked hypertensionRobert A Phillips
University of Massachusetts Medical School, Worcester, Massachusetts, USA
Ann N Y Acad Sci 1254:115-22. 2012..Masked hypertension is associated with worse outcome. Ambulatory BP monitoring for those at risk for masked hypertension needs to be incorporated into guidelines...
- Treating hypertension in patients with left ventricular dysfunction: hitting the fairway and avoiding the roughSamuel W Joffe
University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
Curr Heart Fail Rep 10:157-64. 2013....
- Left ventricular hypertrophy by electrocardiography and echocardiography in the African American Study of Kidney Disease Cohort StudyRicardo Esquitin
Beth Israel Deaconess Medical Center, Boston, MA, USA
J Am Soc Hypertens 6:193-200. 2012..0%. Consistent with findings in a general population, left ventricular hypertrophy by electrocardiography had low sensitivity and high specificity in this cohort of African Americans with hypertensive kidney disease...
- Reducing the risk of stroke through appropriate targets and treatmentsMichael H Davidson
Prev Cardiol 10:215-21. 2007....
- Body weight changes with beta-blocker use: results from GEMINIFranz H Messerli
St Luke s Roosevelt Hospital Center, New York City, NY 10019, USA
Am J Med 120:610-5. 2007....
- New-onset diabetes mellitus less deadly than elevated blood pressure? Following the evidence in the administration of thiazide diureticsRobert A Phillips
Arch Intern Med 166:2174-6. 2006
- Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) TrialKeith Norris
Charles R Drew University of Medicine and Science, Lynwood, CA 90262, USA
Am J Kidney Dis 48:739-51. 2006..Patients with chronic kidney disease are at increased risk for cardiovascular (CV) events...
- High-risk African Americans with multiple risk factors for cardiovascular disease: challenges in prevention, diagnosis, and treatmentRichard Allen Williams
Department of Medicine, The David Geffen School of Medicine at UCLA, Minority Health Institute, Los Angeles, California, USA
Ethn Dis 16:633-9. 2006..quot; The AAMRP poses clinical and public health challenges for healthcare providers. We provide clinical and public health strategies for early detection and aggressive management of AAMRP...
- Hypertensive heart diseaseJoseph A Diamond
Division of Cardiology, Long Island Jewish Hospital, New Hyde Park, New York 10040, USA
Hypertens Res 28:191-202. 2005..The purpose of this review is to summarize current and emerging approaches to the pathophysiology and treatment of hypertensive heart disease...
- Quality: the need for intelligent effortsLawrence Baruch
Arch Intern Med 165:1455-6. 2005
- Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trialJackson T Wright
Case Western Reserve University, Department of Medicine, University Hospitals of Cleveland and the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106 5014, USA
JAMA 288:2421-31. 2002..Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD...
- The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertensionRobert A Phillips
Department of Medicine, Lenox Hill Hospital and New York University School of Medicine, New York, NY 10021, USA
J Clin Hypertens (Greenwich) 5:17-23. 2003....
- The rationale and design of the AASK cohort studyLawrence J Appel
Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland, 21205, USA
J Am Soc Nephrol 14:S166-72. 2003..Such results might eventually lead to new strategies that delay or prevent ESRD...
- Regression of left ventricular hypertrophy: are there preferred drugs?Joseph A Diamond
Department of Medicine, Division of Cardiology, Long Island Jewish Medical Center, 270 05 76th Avenue, New Hyde Park, NY 11040, USA
Curr Hypertens Rep 5:368-71. 2003..New avenues of research, based on combination antihypertensive therapy and on a more sophisticated understanding of the molecular mechanisms of LVH, may yield new pharmacologic approaches to regressing LV mass...
- Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy studyBertram Pitt
University of Michigan Health System, Ann Arbor, Mich, USA
Circulation 108:1831-8. 2003..This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension...
- Treatment of octogenarians: should we and howRobert A Phillips
Lenox Hill Hospital and New York University School of Medicine, New York, NY, USA
J Clin Hypertens (Greenwich) 6:267-73; quiz 274-5. 2004
- Antihypertensive drugs and the heartJoseph A Diamond
Nuclear Cardiology, Long Island Jewish Medical Center, New Hyde Park, NY 10040, USA
Curr Cardiol Rep 6:409-15. 2004..This review summarizes current and emerging approaches to the treatment of individuals with hypertensive heart disease...
- Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trialGeorge L Bakris
Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
JAMA 292:2227-36. 2004..Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers...
- Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudyMichael H Olsen
Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, Copenhagen, Denmark
J Hypertens 23:891-8. 2005..We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction...
- Screening for depression: this is the heart of the matterGrant R Grissom
Arch Intern Med 165:1214-6. 2005
- Hypertensive emergencies: diagnosis and managementRobert A Phillips
Departmnet of Medicine, Lenox Hill Hospital, NYU School of Medicine, New York, NY 10021, USA
Prog Cardiovasc Dis 45:33-48. 2002..Strategy is supported by evidence-based considerations whenever possible. Where outcome studies are not available, we rely on the rationale derived from relevant clinical research...